The study of expression of CCAT۲-Lnc noncoding gene in HT-۲۹ and HCT-۱۱۶ colorectal cancer cell line with Gemini Curcumin

Backgrounds: Although recent advances in therapy, colorectal cancer remain a leading cause ofdeath in affected people. Curcumin is the main bioactive compound of turmeric that has beenpointed as an impressive agent versus cancer in blocking, slowing down, or reversing thecarcinogenic process. However, its paltry stableness and bioavailability limit therapeuticapplication. We formerly showed that the transfer of curcumin by using Gemini Surfactantsnanoparticles called Gemini curcumin (Gemini-Cur) could improve its solubility, toxic trace ongastric, breast, and ovarian cancer cells.Materials and Methods: In this study, we aimed to look into the anticancer action of Gemini-Cur on CCAT۲-Lnc noncoding gene expression in colorectal cancer cells. The toxicity ofGemini-Cur on HT-۲۹ and HCT۱۱۶ was studied via MTT. Also, real-time PCR and westernblotting were performed to evaluate the expression of the noncoding Lnc-CCAT۲ and theunderlying c-MYC genes.Results: Our data showed that Gemini-Cur enters cells quite rapidly compared to free curcumincrystals, beyond this puts down HT-۲۹ and HCT-۱۱۶ cells proliferation in a time- and dosedependentmanner (p < ۰.۰۰۱). The IC۵۰ values, as well as metastasis assays, showed thatGemini-Cur decreased the expression level of the lnc-CCAT۲ and c-MYC genes and decreasedmRNA and protein level of the c-MYC gene (p < ۰.۰۰۰۱).Conclusion: in the main, our findings showed that not only Gemini-Cur represses theproliferation of cancer cells but also inducts of metastasis and could be considered as novelnano-formulated phytochemical for cancer targeting.

کلیدواژه ها:

CCAT۲ ، Gemini-curcumin ، colorectal cancer